Tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and tumor xenografts

Biochemical Pharmacology

Volumn 73, Issue 1, 2007, Pages 44-55

  Taverna, Pietro ^a   Rendahl, Katherine ^a   Jekic McMullen, Dragana ^a   Shao, Yi ^a   Aardalen, Kim ^a   Salangsang, Fernando ^a   Doyle, Laura ^a   Moler, Eddie ^a   Hibner, Barbara ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Colon cancer; Combination chemotherapy; Fluoropyrimidines; FMdC; Nucleoside analogs; Tezacitabine

Indexed keywords

CAPECITABINE; DNA; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; TEZACITABINE; THYMIDINE PHOSPHORYLASE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL KILLING; CELL STRAIN HCT116; CLONOGENESIS; CLONOGENIC ASSAY; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPONSE SURFACE METHOD; STATISTICAL SIGNIFICANCE; TUMOR XENOGRAFT;

APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DEOXYCYTIDINE; DNA; DNA DAMAGE; FLOXURIDINE; FLUOROURACIL; HUMANS; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRANSPLANTATION, HETEROLOGOUS;

EID: 33845221675     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.09.009     Document Type: Article

References (41)

1. Sampath D., Rao V.A., and Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 22 56 (2003) 9063-9074
2. Peters G.J., van der Wilt C.L., van Moorsel C.J., Kroep J.R., Bergman A.M., and Ackland S.P. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87 2/3 (2000) 227-253
3. Kanazawa J., Takahashi T., Akinaga S., Tamaoki T., and Okabe M. The relationship between the antitumor activity and the ribonucleotide reductase inhibitory activity of (E)-2′-deoxy-2′-(fluoromethylene) cytidine, MDL 101,731. Anticancer Drugs 9 7 (1998) 653-657
4. Zhou Y., Achanta G., Pelicano H., Gandhi V., Plunkett W., and Huang P. Action of (E)-2′-deoxy-2′-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response. Mol Pharmacol 61 1 (2002) 222-229
5. Takahashi T., Nakashima A., Kanazawa J., Yamaguchi K., Akinaga S., Tamaoki T., et al. Metabolism and ribonucleotide reductase inhibition of (E)-2′-deoxy-2′-(fluoromethylene)cytidine, MDL 101,731, in human cervical carcinoma HeLa S3 cells. Cancer Chemother Pharmacol 41 4 (1998) 268-274
6. Piepmeier J.M., Rabidou N., Schold Jr. S.C., Bitonti A.J., Prakash N.J., and Bush T.L. In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor. Cancer Res 56 2 (1996) 359-361
7. Kotchetkov R., Krivtchik A.A., Cinatl J., Kornhuber B., and Cinatl Jr. J. Selective cytotoxic activity of a novel ribonucleoside diphosphate reductase inhibitor MDL-101,731 against thyroid cancer in vitro. Folia Biol (Praha) 45 5 (1999) 185-191
8. Skierski J.S., Koronkiewicz M., and Grieb P. Tezacitabine blocks tumor cells in G1 and S phases of the cell cycle and induces apoptotic cell death. Acta Pol Pharm 62 3 (2005) 195-205
9. Bitonti A.J., Dumont J.A., Bush T.L., Cashman E.A., Cross-Doersen D.E., Wright P.S., et al. Regression of human breast tumor xenografts in response to (E)-2′-deoxy-2′-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase. Cancer Res 54 6 (1994) 1485-1490
10. Bitonti A.J., Bush T.L., Lewis M.T., and Sunkara P.S. Response of human colon and prostate tumor xenografts to (E)-2′-deoxy-2′-(fluoromethylene) cytidine, an inhibitor of ribonucleotide reductase. Anticancer Res 15 4 (1995) 1179-1182
11. Coucke P.A., Decosterd L.A., Li Y.X., Cottin E., Chen X., Sun L.Q., et al. The ribonucleoside diphosphate reductase inhibitor (E)-2′-deoxy-(fluoromethylene)cytidine as a cytotoxic radiosensitizer in vitro. Cancer Res 59 20 (1999) 5219-5226
12. Li Y.X., Sun L.Q., Weber-Johnson K., Paschoud N., and Coucke P.A. Potentiation of cytotoxicity and radiosensitization of (E)-2-deoxy-2′-(fluoromethylene) cytidine by pentoxifylline in vitro. Int J Cancer 80 1 (1999) 155-160
13. Coucke P.A., Cottin E., Azria D., Martineau P., Adamer F., Decosterd L.A., et al. Positive interactive radiosensitisation in vitro with the combination of two nucleoside analogues, (E)-2′-deoxy-2′-(fluoromethylene) cytidine and iododeoxyuridine. Eur J Cancer 40 10 (2004) 1572-1580
14. Woessner R.D., Loudy D.E., Wallace C.D., Montgomery L.R., Cross-Doersen D.E., Bush T.L., et al. Decreased vascular endothelial growth factor expression associated with tumor regression induced by (E)-2′-deoxy-2′-(fluoromethylene)cytidine (MDL, 101,731). Oncol Res 9 10 (1997) 543-552
15. Sunkara P.S., Zwolshen J.H., Matthews D.P., and McCarthy J.R. Synergistic antitumor activity of (E)-2′-deoxy-2′(fluoromethylene) cytidine (FMdC, MDL101,731), an inhibitor of ribonucleotide reductase in combination with S phase specific drugs. Proc Am Assoc Cancer Res 33 (1992) Abst. 3088
16. Yu N., Patawaran M.B., la Pena R., Chen J.Y., Tressler R.J., and Jones R.E. Enhanced antitumor activity when combining a novel nucleoside analogue FMdC [(E)-2′-deoxy-2′-(fluoromethylene)cytidine] with other chemotherapeutic agents in human NSLC and colon xenografts. Proc Am Assoc Cancer Res 41 (2000) Abst. 2610
17. Bendell J.C., Eder J.P., Clark J.W., Fidias P., Lynch T.J., Seiden M.V., et al. Phase I dose escalation study of (E)-2′-deoxy-2′-(fluoromethylene) cytidine (tezacitabine) in combination with fluorouracil (5-FU) in patients with advanced solid tumors. Clin Cancer Res 9 16 (2003) Abst. A189
18. Longley D.B., Harkin D.P., and Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3 5 (2003) 330-338
19. Houghton J.A., Harwood F.G., and Tillman D.M. Thymineless death in colon carcinoma cells is mediated via fas signalling. Proc Natl Acad Sci USA 94 15 (1997) 8144-8149
20. Houghton J.A., Houghton P.J., and Wooten R.S. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine. Cancer Res 39 7 Pt 1 (1979) 2406-2413
21. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34 8 (1998) 1274-1281
22. Greco W.R., Bravo G., and Parsons J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47 2 (1995) 331-385
23. Yalowich J.C., and Kalman T.I. Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro. Biochem Pharmacol 34 13 (1985) 2319-2324
24. Collins A.R. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 26 3 (2004) 249-261
25. Littell R.C., Milliken G.A., Stroup W.W., and Wolfinger R.D. SAS system for mixed models (1996), SAS Institute, Cary, NC
26. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., and Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58 4 (1998) 685-690
27. Grant S. Ara-C: cellular and molecular pharmacology. Adv Cancer Res 72 (1998) 197-233
28. Storniolo A.M., Enas N.H., Brown C.A., Voi M., Rothenberg M.L., et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85 6 (1999) 1261-1268
29. Faderl S., Gandhi V., Kantarjian H., and Plunkett W. New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif 20 (2002) 37-58
30. Plunkett W., and Gandhi V. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif 19 (2001) 21-45
31. Ruiz van Haperen V.W., Veerman G., Braakhuis B.J., Vermorken J.B., Boven E., Leyva A., et al. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. Eur J Cancer 29A 15 (1993) 2132-2137
32. Bendell J.C., Eder J.P., Clark J.W., Fidias P., Lynch T.J., Seiden M.V., et al. Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors. Cancer 103 9 (2005) 1925-1931
33. Petak I., Tillman D.M., and Houghton J.A. p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin Cancer Res 6 11 (2000) 4432-4441
34. Kuo M.L., Kunugi K.A., Lindstrom M.J., and Kinsella T.J. The interaction of hydroxyurea and iododeoxyuridine on the radiosensitivity of human bladder cancer cells. Cancer Res 55 13 (1995) 2800-2805
35. Bianchi V., Pontis E., and Reichard P. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem 261 34 (1986) 16037-16042
36. Ren Q., Kao V., and Grem J.L. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 4 11 (1998) 2811-2818
37. Heinemann V., Xu Y.Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38 4 (1990) 567-572
38. Sawada N., Fujimoto-Ouchi K., Ishikawa T., Tanaka Y., and Ishitsuka H. Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenografts (2002), American Association for Cancer Research, San Francisco, CA
39. Schilsky R.L., Bertucci D., Vogelzang N.J., Kindler H.L., and Ratain M.J. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol 20 2 (2002) 582-587
40. Hess V., Salzberg M., Borner M., Morant R., Roth A.D., Ludwig C., et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 21 1 (2003) 66-68
41. Meropol N.J., Gold P.J., Diasio R.B., Chen Y.-M., Godfrey T., Hill T., et al. Correlation of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) expression in primary and metastatic sites with response to capecitabine plus irinotecan in patients with colorectal cancer. J Clin Oncol 22 14S (2004) 3520